Viridian Therapeutics, Inc.

US$28.49As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:VRDNHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (18.07%)
Div yield —
ROE (83.71%)
Biotechnology
Beta (5Y) 1.07
PE TTM —
TSR TTM 20.57%
Mkt cap US$3.235B
ROIC (43.29%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$31
9.84%
(52.30%)
Hold 7|10|11|6|4
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.52
0.56
0.59
0.58
22.86%
36.13%
36.54%
25.96%
Revenue$M
230.1
226.1
224.2
231.0
11.03%
4.35%
2.91%
0.98%
Peers (US$3.235B)
Cap (US$)
PE
3.268B
—
Capital
TTM
5Y
10Y
Leveragex
0.748
0.122
0.111
EBIT/Intx
1.669
0.294
0.261
Own earn%
204.41
(41.55)
(50.07)
Sh yield%
15.49
22.84
19.77
Owners
Insiders/Inst%
8.85
22.71
Short interest%
0.76
SBC / revenue%
0.98
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
6
Op margin range%
26–31
$1 testx
—
Incr. ROIC%
5